{"id":"https://openalex.org/W4396587394","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-18-12","title":"Abstract PO3-18-12: Results from a first-in-human study of DAN-222, a novel high-capacity drug conjugate in metastatic breast cancer as monotherapy and in combination with a PARPi [NCT05261269]","display_name":"Abstract PO3-18-12: Results from a first-in-human study of DAN-222, a novel high-capacity drug conjugate in metastatic breast cancer as monotherapy and in combination with a PARPi [NCT05261269]","publication_year":2024,"publication_date":"2024-05-02","ids":{"openalex":"https://openalex.org/W4396587394","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-18-12"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs23-po3-18-12","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-18-12","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-18-12","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Hurvitz","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, Washington, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, Washington, United States,","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003060935","display_name":"Erika Paige Hamilton","orcid":"https://orcid.org/0000-0002-1911-0336","observed_orcids":["https://orcid.org/0000-0002-1911-0336"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika Hamilton","raw_affiliation_strings":["2Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States,","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038208006","display_name":"Timothy Pluard","orcid":"https://orcid.org/0000-0002-3640-3077","observed_orcids":["https://orcid.org/0000-0002-3640-3077"]},"institutions":[{"id":"https://openalex.org/I75421653","display_name":"University of Missouri\u2013Kansas City","ror":"https://ror.org/01w0d5g70","country_code":"US","type":"education","lineage":["https://openalex.org/I75421653"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy Pluard","raw_affiliation_strings":["3Saint Luke\u2019s Cancer Institute, University of Missouri, Kansas City, Missouri, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Saint Luke\u2019s Cancer Institute, University of Missouri, Kansas City, Missouri, United States,","institution_ids":["https://openalex.org/I75421653"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052914934","display_name":"Aki Morikawa","orcid":"https://orcid.org/0000-0002-4764-4896","observed_orcids":["https://orcid.org/0000-0002-4764-4896"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aki Morikawa","raw_affiliation_strings":["4University of Michigan School of Medicine, Ann Arbor, Michigan, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4University of Michigan School of Medicine, Ann Arbor, Michigan, United States,","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090789911","display_name":"Hatem Hussein Soliman","orcid":"https://orcid.org/0000-0001-6644-2264","observed_orcids":["https://orcid.org/0000-0001-6644-2264"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hatem Soliman","raw_affiliation_strings":["5H. Lee Moffitt Cancer Center, Florida, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5H. Lee Moffitt Cancer Center, Florida, United States,","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023027543","display_name":"Kay T. Yeung","orcid":"https://orcid.org/0000-0002-0013-7002","observed_orcids":["https://orcid.org/0000-0002-0013-7002"]},"institutions":[{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kay Yeung","raw_affiliation_strings":["6UC San Diego Health Moores Cancer Center,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6UC San Diego Health Moores Cancer Center,","institution_ids":["https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044108002","display_name":"Adam Brufsky","orcid":"https://orcid.org/0000-0001-8080-7960","observed_orcids":["https://orcid.org/0000-0001-8080-7960","https://orcid.org/0009-0006-2725-3579"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam Brufsky","raw_affiliation_strings":["7UPMC Hillman Cancer Center, University of Pittsburgh Medical Center,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7UPMC Hillman Cancer Center, University of Pittsburgh Medical Center,","institution_ids":["https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078401114","display_name":"Amy Tiersten","orcid":"https://orcid.org/0000-0002-4054-9140","observed_orcids":["https://orcid.org/0000-0002-4054-9140"]},"institutions":[{"id":"https://openalex.org/I4390039328","display_name":"Tisch Cancer Institute","ror":"https://ror.org/0317dzj93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1320796813","https://openalex.org/I4390039328","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy Tiersten","raw_affiliation_strings":["8Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New, New York, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New, New York, United States,","institution_ids":["https://openalex.org/I4390039328"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048296049","display_name":"Wajeeha Razaq","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I49332381","display_name":"University of Oklahoma Health Sciences Center","ror":"https://ror.org/0457zbj98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I49332381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wajeeha Razaq","raw_affiliation_strings":["9Oklahoma university of health Sciences, Oklahoma City, Oklahoma, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Oklahoma university of health Sciences, Oklahoma City, Oklahoma, United States,","institution_ids":["https://openalex.org/I49332381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5096099377","display_name":"Kristen Foye","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kristen Foye","raw_affiliation_strings":["10Dantari, Inc.,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Dantari, Inc.,","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060155223","display_name":"Timothy Hagerty","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Timothy Hagerty","raw_affiliation_strings":["11Dantari, Inc, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Dantari, Inc, California, United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"9_Supplement","first_page":"PO3","last_page":"18"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9146000146865845,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9146000146865845,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.07999999821186066,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/camptothecin","display_name":"camptothecin","score":0.9409999847412109},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.9610000252723694},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8090000152587891},{"id":"https://openalex.org/keywords/niraparib","display_name":"niraparib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9440000057220459},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9089999794960022},{"id":"https://openalex.org/keywords/hrd","display_name":"HRD","score":0.5659999847412109},{"id":"https://openalex.org/keywords/brca-mutations","display_name":"BRCA mutations","score":0.7039999961853027},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6859999895095825},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.7720000147819519},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8550000190734863},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7039999961853027},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5630000233650208}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7573919296264648},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.725282609462738},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6841204166412354},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6177583336830139},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5139376521110535},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5049260258674622},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.46498391032218933},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45709720253944397},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.17327362298965454},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs23-po3-18-12","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-18-12","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-18-12","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3172569210","https://openalex.org/W4322774065","https://openalex.org/W7162555081","https://openalex.org/W2570352383","https://openalex.org/W7154575621","https://openalex.org/W2986675399","https://openalex.org/W4409689587","https://openalex.org/W2751119678","https://openalex.org/W4226305191","https://openalex.org/W4416028948"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Topoisomerase":[2],"I":[3,42],"inhibitors":[4,26],"(Topo":[5],"I)":[6],"have":[7,28,57],"been":[8,29],"shown":[9,30],"to":[10,31,47,145,179,197,386,444,466],"be":[11,32,48,206,445],"highly":[12],"effective":[13,33],"across":[14,389,415],"a":[15,64,90,124,377,448,517,522,537],"broad":[16],"range":[17],"of":[18,40,87,93,116,156,186,240,250,273,327,370,404,410,434,457,472,520,543],"tumors":[19],"including":[20],"breast":[21,36,174,222,529],"cancer.":[22,175,473],"Poly":[23],"(ADP-ribose)":[24],"polymerase":[25],"(PARPi)":[27],"in":[34,161,168,247,376,402,424,429,481,485,527,534],"BRCAm":[35,52],"cancers.":[37],"The":[38,126,176,261,270,368,380,454,474],"combination":[39,121,134,162,255,331,413,427,462,482,535],"Topo":[41],"plus":[43,89],"PARPi":[44,91,282,449,484,538],"is":[45,63,73,128,165],"known":[46],"synergistic":[49],"beyond":[50],"the":[51,74,113,181,199,209,213,287,290,318,330,333,430,440,544],"subtype":[53],"but":[54],"overlapping":[55,149],"myelotoxicities":[56],"prohibited":[58],"successful":[59],"clinical":[60,106,129,190,489],"combinations.":[61,107],"DAN-222":[62,88,99,117,157,371,443,458,480],"novel":[65,523],"therapeutic":[66],"HDC":[67],"(High-capacity":[68],"drug":[69,525],"conjugate)":[70],"whose":[71],"payload":[72],"topoisomerase":[75],"1":[76,154],"inhibitor":[77],"camptothecin":[78],"(CPT).":[79],"Our":[80],"previously":[81],"published":[82],"preclinical":[83],"data":[84,111],"demonstrates":[85,100,439],"synergy":[86],"regardless":[92],"BRCA":[94,234],"or":[95,235,254,426],"HRD":[96,236],"status.":[97,237],"Furthermore,":[98],"reduced":[101,455],"bone":[102],"marrow":[103],"exposure":[104,369],"enabling":[105],"Herein":[108],"we":[109],"present":[110],"for":[112,135,208,442],"first-in-human":[114,518],"study":[115,155,438,519],"as":[118,158,531],"mono-":[119],"and":[120,139,142,160,184,188,212,284,312,353,359,374,408,533],"therapy":[122,256,414,428],"with":[123,131,137,163,172,219,257,399,406,412,447,463,469,479,483,536],"PARPi.":[125],"expectation":[127],"benefit":[130],"this":[132,435],"complimentary":[133],"patients":[136,171,244,280,405,411,468],"HRD+":[138],"HRD-":[140],"tumors,":[141],"not":[143],"restricted":[144],"BRCAm,":[146],"while":[147],"minimizing":[148],"myelotoxicities.":[150],"Methods:":[151],"A":[152],"phase":[153,201,433],"monotherapy":[159,251,288,407,425,532],"niraparib":[164,258],"being":[166],"conducted":[167],"heavily":[169],"pretreated":[170],"metastatic":[173,221,528],"objectives":[177],"are":[178],"evaluate":[180],"safety,":[182],"tolerability,":[183],"pharmacokinetics":[185],"DAN-222,":[187,521],"initial":[189],"activity":[191,393,477],"based":[192],"on":[193,226,233],"RECIST":[194],"v1.1":[195],"criteria":[196],"determine":[198],"recommended":[200],"2":[202],"dose.":[203],"PK":[204],"will":[205,459],"characterized":[207],"total":[210],"conjugated":[211],"unconjugated":[214],"CPT.":[215],"Adults":[216],"(\u226518":[217],"years)":[218],"HER2-negative":[220],"cancer":[223,530],"that":[224],"progressed":[225],"standard":[227],"therapies":[228,465],"were":[229,281,295,336,422],"enrolled,":[230],"without":[231],"restriction":[232],"Results:":[238],"As":[239],"June":[241],"2023,":[242],"30":[243],"had":[245],"enrolled":[246],"dose":[248,395,417,431],"escalation":[249,396,432],"(2-16":[252],"mg/m2)":[253],"(100":[259],"mg).":[260],"median":[262,271],"age":[263],"was":[264,277,324,361,372,397],"61.5":[265],"years":[266],"old":[267],"(range,":[268],"36-75).":[269],"number":[272],"prior":[274],"treatment":[275],"lines":[276],"6.":[278],"All":[279],"na\u00efve":[283],"BRCAwt.":[285],"In":[286,329],"cohorts,":[289,332],"hematological":[291,334],"adverse":[292,320,366],"events":[293,321],"(AEs)":[294],"neutropenia":[296,347],"(28%;":[297],"grade":[298,349],"[Gr]":[299],"\u22653:":[300,305,310,316,340,345,351,357],"17%),":[301,341],"thrombocytopenia":[302,342],"(22%;":[303],"Gr":[304,309,315,322,339,344,350,356,363],"6%)":[306],"anemia":[307,337],"(17%;":[308,343],"0%),":[311,317],"lymphopenia":[313,354],"(11%;":[314],"non-hematologic":[319,365],"\u22653":[323,364],"one":[325],"case":[326],"cystitis.":[328],"AEs":[335],"(25%;":[338],"8%),":[346,352],"(8%;":[348],"8%;":[355],"0%)":[358],"there":[360],"no":[362],"events.":[367],"linear":[373],"increased":[375],"dose-proportional":[378],"manner.":[379],"mean":[381],"half-life":[382],"ranged":[383],"from":[384,516],"25.2":[385],"33.5":[387],"hours":[388],"all":[390,416],"cohorts.":[391],"Clinical":[392],"during":[394],"demonstrated":[398],"stable":[400],"disease":[401],"28%":[403],"67%":[409],"levels.":[418],"Conclusions:":[419],"No":[420],"DLTs":[421],"observed":[423],"study.":[436],"This":[437],"feasibility":[441],"combined":[446],"at":[450],"clinically":[451],"relevant":[452],"doses.":[453],"myelotoxicity":[456],"also":[460],"enable":[461],"other":[464,470],"treat":[467],"types":[471],"promising":[475],"antitumor":[476],"seen":[478],"BRCAwt,":[486],"supports":[487],"continued":[488],"development.":[490],"Citation":[491],"Format:":[492],"Sara":[493],"Hurvitz,":[494],"Erika":[495],"Hamilton,":[496],"Timothy":[497,513],"Pluard,":[498],"Aki":[499],"Morikawa,":[500],"Hatem":[501],"Soliman,":[502],"Kay":[503],"Yeung,":[504],"Adam":[505],"Brufsky,":[506],"Amy":[507],"Tiersten,":[508],"Wajeeha":[509],"Razaq,":[510],"Kristen":[511],"Foye,":[512],"Hagerty.":[514],"Results":[515],"high-capacity":[524],"conjugate":[526],"[NCT05261269]":[539],"[abstract].":[540],"In:":[541],"Proceedings":[542],"2023":[545,551],"San":[546,554],"Antonio":[547],"Breast":[548],"Cancer":[549,560],"Symposium;":[550],"Dec":[552],"5-9;":[553],"Antonio,":[555],"TX.":[556],"Philadelphia":[557],"(PA):":[558],"AACR;":[559],"Res":[561],"2024;84(9":[562],"Suppl):Abstract":[563],"nr":[564],"PO3-18-12.":[565]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2024-05-03T00:00:00"}